HBV Citations List: February 2024

Literature Citations

1. Identification and Assessment of the 1,6-Dihydroxy-pyridin-2-one Moiety as Privileged Scaffold for HBV Ribonuclease H Inhibition. Giannakopoulou, E., V. Pardali, T.C. Edwards, M. Woodson, R. Tajwar, J.E. Tavis, and G. Zoidis. Antiviral Research, 2024. 223: 105833. PMID[38325606].
[PubMed]. HBV_02_2024.

2. New Facet of CARs: HBV-Specific CARs as Inhibitors of Virus Morphogenesis and Release. Hildt, E. and J. Hu. Gut, 2024. 73(4): p. 566-567. PMID[38253479].
[PubMed]. HBV_02_2024.

3. Intrahepatic Homeobox Protein MSX-1 Is a Novel Host Restriction Factor of Hepatitis B Virus. Shen, Z., S. Zhang, Z. Gao, X. Yu, J. Wang, S. Pan, N. Kang, N. Liu, H. Xu, M. Liu, Y. Yang, Q. Deng, J. Liu, Y. Xie, and J. Zhang. Journal of Virology, 2024. 98(2): e0134523. PMID[38226815]. PMID[PMC10878074].
[PubMed]. HBV_02_2024.

4. Catenulopyrizomicins, New anti-Hepatitis B Virus Compounds, from the Rare Actinomycete catenuloplanes Sp. Mm782l-181f7. Yamasaki, M., R. Sawa, H. Muramatsu, Y. Yamamoto, M. Umekita, Y. Kubota, Y. Kanegae, and M. Igarashi. The Journal of Antibiotics, 2024. 77(2): p. 85-92. PMID[38008738].
[PubMed]. HBV_02_2024.

Patent Citations

This month, no relevant HBV patents were identified.